Find out what Mozobil could do for you

Mozobil is approved by the FDA to be used in combination with another
agent (granulocyte‑colony stimulating factor (G-CSF) to
mobilize hematopoietic stem cells to the peripheral blood for collection
and subsequent autologous transplantation in patients living with
non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).

Learn how Mozobil could help

Supporting you through stem cell mobilization

Our passion is to improve access to medicines and provide support. Explore available resources, including Sanofi Patient Connection™.

Explore Resources